Back to search
FDAFDA · Food and drugs·Recall number D-0304-2017

Testosterone Cypionate/Enanthate/Propionate, 160 mg/20 mg/20 mg/mL, (5 ML). Compounded by Tri-Coast Pharmacy

Published January 11, 2017 · Recall initiated: November 17, 2016

Summary

FDA records drug Class II recall D-0304-2017, published January 11, 2017 and initiated November 17, 2016. Recalling firm: Tri-Coast Pharmacy; Status: Ongoing; Reported quantity: 882 vials; Lot: Recall includes all sterile products compounded between 05/17/2016 and 11/17/2016. Known lot codes (Exp Date): 06082016C (11/09/2016), 07222016B (01/18/2017), 09012016A (02/28/2017), 06012016C (11/09/2016), 08042016E (01/31/2017), 10032016A (04/01/2017). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Tri-Coast Pharmacy
Distributor
Nationwide
Lot
Recall includes all sterile products compounded between 05/17/2016 and 11/17/2016. Known lot codes (Exp Date): 06082016C (11/09/2016), 07222016B (01/18/2017), 09012016A (02/28/2017), 06012016C (11/09/2016), 08042016E (01/31/2017), 10032016A (04/01/2017).
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Testosterone Cypionate/Enanthate/Propionate, 160 mg/20 mg/20 mg/mL, (5 ML). Compounded by Tri-Coast Pharmacy recalled?

Yes. FDA published recall D-0304-2017 on January 11, 2017. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit